Comparative molecular similarity indices analysis for predicting the antihyperglycemic activity of thioglitazones

Medicinal Chemistry Research

Volumn 19, Issue 8, 2010, Pages 1000-1010

  Prashantha Kumar, B R ^a   Nanjan, M J ^a  

^a JSS COLLEGE OF PHARMACY   (India)

Author keywords

Antihyperglycemic activity; Comparative molecular field analysis; PPAR c; Thioglitazones; Three dimensional quantitative structure activity relationship

Indexed keywords

5 (PYRIDIN 3 YLMETHYL) 1,3 THIAZOLIDINE 2,4 DIONE DERIVATIVE; 5 [4 (2 PHENYLETHOXY)BENZYL] 1,3 THIAZOLIDINE 2,4 DIONE DERIVATIVE; 5 BENZYL 1,3 THIAZOLIDINE 2,4 DIONE DERIVATIVE; ANTIDIABETIC AGENT; GLITAZONE DERIVATIVE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; UNCLASSIFIED DRUG;

ANTIHYPERGLYCEMIC ACTIVITY; ARTICLE; COMPARATIVE MOLECULAR SIMILARITY INDICES ANALYSIS; DRUG DESIGN; DRUG MECHANISM; DRUG POTENCY; DRUG SCREENING; DRUG STRUCTURE; ELECTRIC POTENTIAL; HYDROGEN BOND; HYDROPHOBICITY; MOLECULAR MODEL; NONHUMAN; PREDICTION; QUANTITATIVE STRUCTURE ACTIVITY RELATION; STEREOSPECIFICITY; STRUCTURE ANALYSIS; TECHNIQUE;

EID: 78650718197     PISSN: 10542523     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00044-009-9246-0     Document Type: Article

References (21)

1. Chen HF, Li Q, Yao XJ, Fan BT, Yuan SG, Panaye A, Doucet JP (2003) 3D-QSAR and docking study of the binding mode of steroids to progesterone receptor in active site. QSAR Comb Sci 22:604-613
2. Chen HF, Li Q, Yao XJ, Fan BT, Yuan SG, Panaye A, Doucet JP (2004) CoMFA/CoMSIA/HQSAR and docking study of the binding mode of selective cyclooxygenase (Cox-2) inhibitors. QSAR Comb Sci 23:36-55
3. Clark M, Cramer RD III, Van Opdenbosch N (1989) Validation of the general purpose Tripos 5.2 forcefield. J Comput Chem 10:982-1012
4. Clark M, Cramer RD III, Jones DM, Patterson DE, Simeroth PE (1990) Comparitive molecular field analysis (CoMFA). Toward its use with 3D-structural databases. Tetrahedron Comput Methodol 3:47-59
5. Cramer RD III, Bunce JD, Patterson DE, Frank LE (1988a) Crossvalidation, bootstrapping, and partial least squares compared with multiple regression in conventional QSAR studies. Quant Struct Act Relat 7:18-25
6. Cramer RD III, Patterson DE, Bunce JD (1988b) Comperative molecular field analysis (CoMFA): effect of shape on binding of steroids to carried protein. J Am Chem Soc 110:5959-5967
7. Delerive P, Fruchart J, Staels B (2001) Peroxisome proliferator-activated receptors in inflammation control. J Endocrinol 169:453-459
8. Evans RM, Barish GD, Wang YX (2004) PPARs and the complex journey to obesity. Nat Med 10:355-361
9. Gasteiger J, Marsili M (1980) Iterative partial equalization of orbital electronegativity a rapid access to atomic charges. Tetrahedron 36:3219-3228
10. James PT (2004) Obesity: the worldwide epidemic. Clin Dermatol 22:276-280
11. Kahn SE, Hull RL, Utzschneider (2006) Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature 444:840-846
12. Kanoh Y, Bandyopadhyay G, Sajan MP, Standaert ML, Farese RV (2000) Thiazolidinedione treatment enhances insulin effects on protein kinase C-zetz/lambda activation and glucose transport in adipocytes of nondiabetic and goto-kakizaki type II diabetic rats. J Biol Chem 275:16690-16696
13. Martens FM, Visseren FL, Lemay J, de Koning EJ, Rabelink TJ (2002) Metabolic and additional vascular effects of thiazolidinediones. Drugs 62:1463-1480
14. Miyazaki Y, Mahankali A, Matsuda M, Glass L, Mahankali S, Ferrannini E, Cusi K, Mandarino LJ, DeFronzo RA (2001) Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone. Diabetes Care 24:710-719
15. Prashantha Kumar BR, Nanjan MJ (2008) QSAR study on thiazolidine-2,4- dione derivatives for their antihyperglycemic activity. Indian J Pharm Sci 70(5):565-571
16. Prashantha Kumar BR, Praveen TK, Nanjan MJ, Karvekar MD, Suresh B (2007) Serum glucose and triglyceride lowering activity of some novel glitazones against dexamethasone-induced hyperlipidemia and insulin resistance. Indian J Pharmacol 39:299-302
17. Prashantha Kumar BR, Bijoy JD, Jensen V, Praveen TK, Suresh B, Nanjan MJ (2008) CoMFA Study on thiazolidine-2,4-diones for their antihyperglycemic activity. Lett Drug Design Discov 5:79-87
18. Staels B, Dallongeville J, Auwerx J, Schoonjans K, Leitersdorf E, Fruchart JC (1998) Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 98:2088-2093
19. Standaert ML, Kanoh Y, Sajan MP, Bandyopadhyay G, Farese RV (2002) Cbl, IRS-1, and IRS-2 Mediate effects of rosiglitazone on PI3 K, PKC-lambda, and glucose transport in 3T3/L1 adipocytes. Endocrinology 143(5):1705-1716
20. Takashi S, Katsutoshi M, Eiko I, Yasuo S, Takeshi F, Yutaka K (1982) Studies on antidiabetic agents. II. Synthesis of 5-[4-(1- methylecyclohexylmethoxy)-benzyl]-thiazolidin-2,4-dione (ADD-3878) and its derivatives. Chem Pharm Bull 30(10):3580-3600
21. Weinstein SP, Holland A, O'Boyle E, Haber RS (1993) Effects of thiazolidinediones on glucocorticoidinduced insulin resistance and GLUT4 glucose transporter expression in rat skeletal muscle. Metabolism 42:1365-1369